Table A1 Sensitivity and specificity of each methylation marker for overall CpG island methylator phenotype (CIMP) status.
| Marker | Total No | CIMP (six markers) | CIMP (five markers. No MGMT) | |||
|---|---|---|---|---|---|---|
| Positive (⩾4/6) | Negative (⩽3/6) | Positive (⩾4/5) | Negative (⩽3/5) | |||
| Total No | 460 | 94 (20%)* | 366 | 78 (17%)* | 382 | |
| CACNA1G | Positive | 108 | 84 (89%)† | 24 | 76 (97%)† | 32 |
| Negative | 352 | 10 | 342 (93%)‡ | 2 | 350 (92%)‡ | |
| CDKN2A | Positive | 147 | 83 (88%)† | 64 | 71 (91%)† | 75 |
| Negative | 313 | 11 | 302 (83%)‡ | 7 | 307 (80%)‡ | |
| CRABP1 | Positive | 164 | 93 (99%)† | 71 | 78 (100%)† | 86 |
| Negative | 296 | 1 | 295 (81%)‡ | 0 | 296 (77%)‡ | |
| MGMT | Positive | 183 | 58 (62%)† | 125 | – | – |
| Negative | 277 | 36 | 241 (66%)‡ | – | – | |
| MLH1 | Positive | 70 | 60 (64%)† | 10 | 58 (74%)† | 12 |
| Negative | 390 | 34 | 356 (97%)‡ | 20 | 370 (97%)‡ | |
| NEUROG1 | Positive | 155 | 88 (94%)† | 67 | 77 (99%)† | 78 |
| Negative | 305 | 6 | 299 (82%)‡ | 1 | 304 (80%)‡ | |
*Prevalence of CIMP.
†Sensitivity defined by “(the number of CIMP cases positive for a given marker)/(the number of all CIMP positive cases)”.
‡Specificity defined by “(the number of non‐CIMP (CIMP negative) cases negative for a given marker)/(the number of all non‐CIMP cases)”.